Sanjivani Paranteral Ltd Q3 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w7o7bm5fp841nicb8w12wh1g.pdf

Key Takeaways


Joint Ventures: The HAL Blueprint & Pipeline

Ashwani Khemka: "We are the first for PPD model with the government PSUs in India. And the moment this is opened, we have already 2 or 3 in pipeline. This will be announced in the short duration. These are bigger JVs than these HAL."

Revenue Mix & Margin Dynamics

Srivardhan Khemka: "So what happened this quarter was basically we had a few previous tenders, which were pending from the governments in the Latin American region, and those were supplied. So what happened was injectable did grow, but it was the lower margin injectables that was being supplied."

Geographic Expansion & Market Access


Product & Plant Infrastructure

Ashwani Khemka: "we completed this plant within a period of 10 months, which was a tough task, and it is spread in the almost 18 acres area."

Guidance & Commitments

CommitmentSpecificsTimeline
Base business CAGRGrow at 25% CAGROver the next couple of years
HAL JV EBITDA margin19%-20%Maintained; Q3 dip was trial-related, not a revision
HAL JV commercial ramp-up30-35% capacity initially, full ramp-up in minimum 6-7 monthsInitial phase through April/May; full ramp-up thereafter
HAL JV final approvalsApprovals expected in 7-8 daysEnd of February/early March
New JV announcements2-3 bigger JVs than HAL to be announced"Short duration"
JV margin accretionMargins to improve a little bitStarting Q4
Prague JV financial disclosureNumbers shared with stakeholdersAfter annual March balance sheet

Key Metrics

MetricQ3 FY25
Revenue₹17.4 cr, +15.9% YoY
EBITDA₹2.86 cr, +29.3% YoY
EBITDA margin16.5%, vs 14.8% in Q3 FY24
Profit after tax₹1.9 cr, +15.5% YoY
9M FY25 revenue₹51.92 cr, +25% YoY
9M FY25 EBITDA₹8.53 cr, +30.2% YoY
9M FY25 EBITDA margin16.4%, vs 15.8% in 9M FY24
9M FY25 profit after tax₹5.9 cr, +20.4% YoY
Export/domestic mix84.1% / 15.9%
Injectable/tablet/nutraceutical mix74.5% / 19.6% / 5.6%
Base business annual revenue~₹65 cr, nearly doubled from ₹35 cr in FY23
Navi Mumbai plant capacity utilization75%
Dehradun plant capacity utilization45%
New product registrations filed16 in French Africa
HAL JV installed capacity0.5 cr bottles per month, ramp-up starting at 30-35% utilization
HAL JV expected top line at full capacity₹100-110 cr
HAL JV EBITDA margin guidance19-20%, with initial quarter at ~16% due to trial costs